Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.
News|Articles|July 27, 2026
Dosing begins in phase 2a/2b trial of YB-101 after Yarrow Bioscience closes merger with VYNE Therapeutics
Author(s)Lynda Charters
A study of YB-101, a potential treatment for both Graves' disease and thyroid eye disease, has begun dosing the first patients. The molecule receive Fast Track Designation from the FDA.
Advertisement
Advertisement
Yarrow Bioscience announced in a press release that it closed its merger with VYNE Therapeutics and dosing of patients began in a phase 2a/b trial (NCT07682896) of
Related to this article
The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.
The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA gains.
From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic atrophy, these are the retinal gene therapy milestones of 2026.
Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.
Few people starting tamoxifen require an ophthalmic evaluation during the following year.
Clinical Forum cases examine symptoms, progression, and treatment response.
Advertisement
Advertisement